Related Experiment Videos

Thiazolidinediones may not reduce diabetes incidence in type 1 diabetes

Toshikatsu Shigihara1, Yoshiaki Okubo, Yasuhiko Kanazawa

  • 1Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Annals of the New York Academy of Sciences
|November 30, 2006
PubMed

Insights

Pioglitazone did not show an advantage over metformin in preventing diabetes in non-obese diabetic (NOD) mice. Further research is needed before using thiazolidinediones for slowly progressive insulin-dependent diabetes mellitus (SPIDDM).

Area of Science:

  • Immunology
  • Endocrinology
  • Pharmacology

Background:

  • Thiazolidinediones, like troglitazone, may prevent diabetes by modulating T-helper 1/T-helper 2 (Th1/Th2) immune responses.
  • Pioglitazone is a thiazolidinedione used to improve glycemic control by reducing insulin resistance.
  • Metformin is a common diabetes medication with no known immunological effects.

Purpose of the Study:

  • To investigate if pioglitazone is effective in preventing diabetes in non-obese diabetic (NOD) mice.
  • To compare the potential diabetes-preventative effects of pioglitazone with metformin.
  • To explore the impact of pioglitazone on Th1/Th2 balance in the context of diabetes prevention.

Main Methods:

  • Female NOD mice were treated orally with either pioglitazone or metformin.
  • Insulitis scores were assessed to evaluate pancreatic inflammation.
  • Cytokine profiles from splenocytes and pancreatic tissue were analyzed.
  • The incidence of diabetes was determined after cyclophosphamide-induced acceleration.

Main Results:

  • Pioglitazone did not demonstrate a superior effect compared to metformin in preventing Th1 immune skewing.
  • Neither drug showed a significant advantage over the other in preventing the development of diabetes in this model.
  • Analysis of insulitis scores and cytokine expression did not reveal a unique benefit of pioglitazone.

Conclusions:

  • Pioglitazone does not appear to offer an advantage over metformin in preventing diabetes in NOD mice.
  • The proposed mechanism involving Th1/Th2 balance modulation by pioglitazone was not clearly demonstrated in this study.
  • Current evidence does not support the application of thiazolidinediones for slowly progressive insulin-dependent diabetes mellitus (SPIDDM) without further investigation.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...